Stay up to date with our latest research breakthroughs,
awards, and publications.
🏆 Award
eNIOS awarded 1st prize of Pfizer's accelerator
Start4Health
eNIOS was awarded the 1st prize of Start4Health, an accelerator organized by Pfizer's Center of
Digital Innovation.
Start4Health focused on Digital Health and targeted startup companies that develop solutions that
can tackle challenges
of the health industry, improve the digital experience of patients and promote wellness through
technology.
eNIOS worked closely with the programme's experts to demonstrate the potential of our multi-omic
platform
in precision medicine applications.
Press
Analysis of biological big data in precision medicine and
drug development
Published in HEALTH by Next Deal (in Greek). Read our team's perspective on how biological big data
analysis is
transforming precision medicine approaches and accelerating the drug development pipeline through
advanced bioinformatics tools.
Publication
Regulated IRE1α-dependent decay (RIDD)-mediated
reprogramming of lipid metabolism in cancer
Our new paper in Nature Communications involving functional
transcriptomic analysis
with the e-NIOS BioInfoMiner platform. BioInfoMiner enables an automated data- and biology-driven
interpretation of omic data,
making evident which are the crucial genes driving phenotypes and how they interact.
Integration of Raman spectra with transcriptome data in
glioblastoma multiforme defines tumour subtypes and predicts patient outcome
Glioblastoma Multiforme is the most aggressive form of primary brain tumors. Raman spectroscopy is
an imaging technique
applied to assess molecular compositions of living cells. This study integrates Raman spectral data
with transcriptome
analysis using the e-NIOS BioInfoMiner platform to characterize tumour subtypes and predict patient
outcomes.
🏆 Award
Award to e-NIOS by the HDB – Hellenic Development Bank SA
and Researcher’s Night
e-NIOS received a prestigious award recognized by the Hellenic Development Bank SA during the
Researcher’s Night event, highlighting our innovative contributions to the biotech sector in Greece.
Publication
Epigenetics in Breast Cancer Therapy-New Strategies and
Future Nanomedicine Perspectives
As a partner of the international INNOCENT project, e-NIOS contributes to developing innovative
multifunctional
nano-pharmaceuticals to overcome low efficacy and frequent relapses in breast cancer treatment.
Publication
BioInfoMiner elucidates the role of the early secretory
pathway in SARS-CoV-2 infection
In collaboration with international partners, we analyzed the contribution of molecular machines
operating in the
early secretory pathway to the biogenesis of SARS-CoV-2, identifying potential antiviral targets.
RA-map: a state-of-the-art interactive knowledge base for
rheumatoid arthritis
BioInfoMiner was used for topological, functional and pharmacogenomic analysis to build RA-map, a
fully annotated,
expert-validated knowledge base for Rheumatoid Arthritis in the form of a molecular map.
Publication
New publication on bioinformatic analysis of phage display
experiments
Introducing PepSimili, an integrated workflow tool which performs mapping of massive peptide
repertoires
on whole proteomes and delivers a streamlined biological interpretation.
Publication
New e-NIOS’ study suggests a therapeutic approach for
Crohn’s disease
Published in EMBO Molecular Medicine, our study identifies
how regulated secretion of AGR2 links proteostasis with inflammation in Crohn’s disease.
Press
Seven Bridges & e-NIOS Partnership to Break the Biomarker
Bottleneck
Strategic partnership announced towards data-driven discovery of biomarker signatures, integrating
BioInfoMiner into the leading Seven Bridges biomedical data platform.
A high-impact paper in Cell Metabolism involving a
BioInfoMiner-derived biomarker signature demonstrating how dietary restriction impacts tumor growth.
Publication
Dual IRE1 RNase functions dictate glioblastoma development
BioInfoMiner analysis validates proteostasis imbalance as a driver of tumor aggressiveness in
Glioblastoma (EMBO Molecular Medicine).
Press
Greek Firm e-NIOS Offering Computational Methods to
Prioritize Gene Targets
Feature article in GenomeWeb highlighting our innovative
approach to prioritizing
gene targets for multiple markets in the pharmaceutical industry.